ClinicalTrials.gg
CompletedNCT05310422FYDESUpdated Sep 9, 2026Results posted

Safety Study of Tivanisiran to Treat Dry Eye

A Phase 3 interventional study of Tivanisiran sodium ophthalmic solution and Vehicle ophthalmic solution in Dry Eye Disease, sponsored by Sylentis, S.A.. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
68th of 473
301 · median 60
Started
2022
with 35 others
Phase 3
77 of 544
1 open now
Registered
404th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 68th largest by enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2022, is one of 77 in phase 3, and was the 404th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).

03

Conditions studied

  • Dry Eye Disease

Keywords

  • siRNA
  • oligonucleotide
  • keratoconjunctivitis sicca
  • SYL1001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age
  • Have given their written consent to participate in the study
  • Use of artificial tears (AT), autologous serum or specific dry eye medications during the last 6 months prior to the selection

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding females with a positive pregnancy test
  • Women of not willing to use a medically acceptable method
  • Currently participating or has participated in another clinical trial within the 2 months prior to inclusion
  • Current, previous chronic or recurrent medical condition that, according to the investigator, might impact on the study
  • Any concomitant treatment or prior ocular procedure or surgery in either eye or alteration of the dose of systemic medications that could interfere in the trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    Tivanisiran sodium ophthalmic solution

    Drug: Tivanisiran sodium ophthalmic solution

  • Placebo comparator
    Vehicle ophthalmic solution

    Drug: Vehicle ophthalmic solution

Interventions

  • DrugTivanisiranStudies of TivanisiranTivanisiran pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 drop in the affected eye(s) once daily

  • DrugVehicle ophthalmic solution

    1 drop in the affected eye(s) once daily

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Subjects With Ocular and Non-ocular Treatment Emergent Adverse Events (TEAEs) for 1 Year

    Time frame: 1 year

07

Results

Posted Sep 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneTivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic Solution
Started20398
Completed18292
Not completed216

Outcome measures

PrimaryNumber and Percentage of Subjects With Ocular and Non-ocular Treatment Emergent Adverse Events (TEAEs) for 1 Year
Time frame:
1 year
Reported as:
Count of participants · Participants
Number and Percentage of Subjects With Ocular and Non-ocular Treatment Emergent Adverse Events (TEAEs) for 1 Year
ParticipantsTivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic Solution
Number and Percentage of Subjects With Ocular and Non-ocular Treatment Emergent Adverse Events (TEAEs) for 1 Year2516

Adverse events

Collected over 1 year. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tivanisiran Sodium Ophthalmic Solution0/203 (0%)7/203 (3.4%)37/203 (18.2%)
Vehicle Ophthalmic Solution0/98 (0%)3/98 (3.1%)31/98 (31.6%)
Most frequent serious events
Most frequent serious events
EventTivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic Solution
AngioedemaSkin and subcutaneous tissue disorders0/2031/98
NephrolithiasisRenal and urinary disorders0/2031/98
Hip fractureInjury, poisoning and procedural complications0/2031/98
VertigoEar and labyrinth disorders1/2030/98
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2030/98
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2030/98
OsteoarthritisMusculoskeletal and connective tissue disorders1/2030/98
Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2030/98
Thoracic vertebral fractureInjury, poisoning and procedural complications1/2030/98
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/2030/98
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic Solution
CovidInfections and infestations8/2038/98
Urinary tract infectionInfections and infestations8/2035/98
NasopharingytisInfections and infestations6/2032/98
OsteoarthritisMusculoskeletal and connective tissue disorders6/2032/98
Posterior capsule opacificationEye disorders0/2032/98
Instilation site painGeneral disorders0/2032/98
HordeolumEye disorders1/2032/98
SinusitisInfections and infestations4/2032/98
Upper respiratory tract infectionInfections and infestations3/2032/98
GastroenteritisInfections and infestations0/2032/98

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
<=18 years000
Between 18 and 65 years8842130
>=65 years11556171
Age, Continuous
Age, Continuous(years)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
Mean63.5 ± 12.964.4 ± 11.563.8 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
Female15978237
Male442064
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
Other — American Indian or Alaska Native000
Other — Asian14418
Other — Native Hawaiian or Other Pacific Islander101
Other — Black or African American251237
Other — White15378231
Other — More than one race101
Other — Unknown or Not Reported9413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
Hispanic or Latino321345
Not Hispanic or Latino17185256
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
United States20398301
Total Corneal Fluorescein Staining (CFS) Scale [0-15]
Total Corneal Fluorescein Staining (CFS) Scale [0-15](units on a scale)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
Mean6.3 ± 2.16.4 ± 2.36.3 ± 2.2
Visual Analogue Scale (VAS) Scale [0-100 mm]
Visual Analogue Scale (VAS) Scale [0-100 mm](units on a scale)Tivanisiran Sodium Ophthalmic SolutionVehicle Ophthalmic SolutionTotal
Mean66.7 ± 15.766.1 ± 17.166.5 ± 16.2
08

Study locations

25 sites
  • Sylentis Investigative Site
    Chandler, Arizona 85021, United States
  • Sylentis Investigative Site
    Phoenix, Arizona 85032, United States
  • FYDES Investigative Site
    Glendale, California 91204, United States
  • Sylentis Investigative Site
    Hemet, California 92545, United States
  • Sylentis Investigative Site
    Los Angeles, California 85032, United States
  • Sylentis Investigative Site
    Murrieta, California 92562, United States
  • Sylentis Investigative Site
    Newport Beach, California 92663, United States
  • FYDES Investigative Site
    Delray Beach, Florida 33484, United States
  • FYDES Investigative Site
    Jacksonville, Florida 32256, United States
  • Sylentis Investigative Site
    Largo, Florida 33773, United States
  • Sylentis Investigative Site
    Morrow, Georgia 30260, United States
  • Sylentis Investigative Site
    Fraser, Michigan 48026, United States
  • Sylentis Investigative Site
    Kansas City, Missouri 64111, United States
  • FYDES Investigative Site
    St Louis, Missouri 63131, United States
  • Sylentis Investigative Site
    Washington, Missouri 63090, United States
  • Sylentis Investigative Site
    Rochester, New York 14618, United States
  • Sylentis Investigative Site
    Asheville, North Carolina 28803, United States
  • Sylentis Investigative Site
    Garner, North Carolina 27529, United States
  • Sylentis Investigative Site
    Cranberry Township, Pennsylvania 16066, United States
  • Sylentis Investigative Site
    Rapid City, South Dakota 57701, United States
  • Sylentis Investigative Site
    Memphis, Tennessee 38119, United States
  • Sylentis Investigative Site
    Austin, Texas 78731, United States
  • FYDES Investigative Site
    El Paso, Texas 79902, United States
  • Sylentis Investigative Site
    San Antonio, Texas 78215, United States
  • Sylentis Investigative Site
    San Antonio, Texas 78230, United States
09

References and documents

Publications

  • Mangwani-Mordani S, Goodman CF, Galor A. Novel Treatments for Chronic Ocular Surface Pain. Cornea. 2023 Mar 1;42(3):261-271. doi: 10.1097/ICO.0000000000003193. Epub 2022 Dec 19. PubMed 36729473 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Oct 2023, 18 months.

Results were first posted in Sep 2026, 2 years 10 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 18 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 5, 2022
StartActual
Mar 24, 2022
Primary completionActual
Oct 11, 2023
CompletionActual
Oct 11, 2023
Results first posted
Sep 9, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05310422
Lead sponsor
Sylentis, S.A.
Responsible party
Sponsor
First posted
Apr 5, 2022
Start date
Mar 24, 2022
Primary completion
Oct 11, 2023
Completion
Oct 11, 2023
Results posted
Sep 9, 2026
Last update
Sep 9, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tivanisiran

Start the discussion